{"denoms":[{"counts":[{"groupId":"BG000","value":"115"},{"groupId":"BG001","value":"113"},{"groupId":"BG002","value":"113"},{"groupId":"BG003","value":"113"},{"groupId":"BG004","value":"454"}],"units":"Participants"}],"groups":[{"description":"Patients receive paclitaxel (pac) IV over 60 minutes once weekly in weeks 1-12. Patients then receive dose-dense doxorubicin hydrochloride IV over 5-10 minutes and cyclophosphamide IV over 5-30 minutes (ddAC) once in weeks 13, 15, 17, and 19.\n\ndoxorubicin hydrochloride: Given IV\n\npaclitaxel: Given IV\n\ncyclophosphamide: Given IV","id":"BG000","title":"Arm 1 (Pac --> ddAC)"},{"description":"Patients receive pac and ddAC as in arm 1. Patients also receive bevacizumab (bev) IV over 30-90 minutes in weeks 1, 3, 5, 7, 9, 11, 13, 15, and 17.\n\ndoxorubicin hydrochloride: Given IV\n\npaclitaxel: Given IV\n\ncyclophosphamide: Given IV\n\nbevacizumab: Given IV","id":"BG001","title":"Arm 2 (Pac + Bev --> ddAC + Bev)"},{"description":"Patients receive pac and ddAC as in arm 1. Patients also receive carboplatin IV over 30 minutes once in weeks 1, 4, 7, and 10.\n\ndoxorubicin hydrochloride: Given IV\n\npaclitaxel: Given IV\n\ncyclophosphamide: Given IV\n\ncarboplatin: Given IV","id":"BG002","title":"Arm 3 (Pac + Carboplatin --> ddAC)"},{"description":"Patients receive pac and ddAC as in arm 1, bev as in arm 2, and carboplatin as in arm 3.\n\ndoxorubicin hydrochloride: Given IV\n\npaclitaxel: Given IV\n\ncyclophosphamide: Given IV\n\nbevacizumab: Given IV\n\ncarboplatin: Given IV","id":"BG003","title":"Arm 4 (Pac + Carboplatin + Bev --> ddAC + Bev)"},{"description":"Total of all reporting groups","id":"BG004","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"11.1","value":"50.2"},{"groupId":"BG001","spread":"10.8","value":"48.3"},{"groupId":"BG002","spread":"10.8","value":"50.9"},{"groupId":"BG003","spread":"9.8","value":"47.1"},{"groupId":"BG004","spread":"10.7","value":"49.1"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"115"},{"groupId":"BG001","value":"113"},{"groupId":"BG002","value":"113"},{"groupId":"BG003","value":"113"},{"groupId":"BG004","value":"454"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"2"},{"groupId":"BG004","value":"3"}],"title":"American Indian or Alaska Native"},{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"5"},{"groupId":"BG002","value":"4"},{"groupId":"BG003","value":"3"},{"groupId":"BG004","value":"13"}],"title":"Asian"},{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"1"}],"title":"Native Hawaiian or Other Pacific Islander"},{"measurements":[{"groupId":"BG000","value":"20"},{"groupId":"BG001","value":"21"},{"groupId":"BG002","value":"27"},{"groupId":"BG003","value":"21"},{"groupId":"BG004","value":"89"}],"title":"Black or African American"},{"measurements":[{"groupId":"BG000","value":"86"},{"groupId":"BG001","value":"84"},{"groupId":"BG002","value":"80"},{"groupId":"BG003","value":"81"},{"groupId":"BG004","value":"331"}],"title":"White"},{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"2"},{"groupId":"BG004","value":"5"}],"title":"More than one race"},{"measurements":[{"groupId":"BG000","value":"5"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"4"},{"groupId":"BG004","value":"12"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race (NIH/OMB)","unitOfMeasure":"Participants"}],"populationDescription":"Using a modified intent-to-treat approach only patients who began protocol treatment (n=443) were included in analyses for neoadjuvant treatment and toxicity. Analyses for surgical endpoints excluded 10 patients who withdrew consent prior to surgery (n=433). All analyses considered patients according to treatment assignment."}